Member Info for Laura2022

Totally agree Latino

LSE have a duty...i reported someone to LSE and to the police when they ranted the most horrific hate inducing posts on LLOYDS last month

It's just incredible PYC is still £1.4mln when lots of companies are £10-20mln who generate little or no revenues

A simple summary which hopefully answers your Q, other holders might correct/add

a) what are the main 'products' and offerings of PYC?

* use A.I and mathematical modelling to design and interpret data for drug companies

*therefore their main business is.software consultancy and work with medium and large companies often with long standing relationships and repeat business.

* they've also been designing a dosing tool to help with dosing regimes and this tool could be adopted by companies and generate significant revenues

* they are also setting up a biostatistics division as interpreting data is becoming more and more essential and in fact required by the FDA etc

b) how do they make money - one-offs, recurring revenue, long term contracts?

* they have moved in last 5 yrs from reliance on on major customer (Merck) to over 20-30 clients, many of which now place repeat business, they are also gaining new customers via social media awareness, industry initiatives.and global conferences

* many holders believe revenue sharing agreements should be the next step potential.

c) what realistically are the prospects for PYC

profits and more importantly for us as PI's the SP over the next 6,12 and 24 months?

* PYC won record contracts for 2023/24 of £900k+ and already have £500k booked in month 1 of this 12mth period (July 2024-june 2025) with estimates being that £1.2mln-£1.3mln should deliver profit

*growing need and awareness of A.I in drug development and now new FDA guidance that drug companies MUST have used data modelling means PYC.is well set for 2024+

d) linked to the above, what would be the catalyst(s) to PYC taking off?

( see the excellent summary from KingHomerJ which I posted 10pm last night )

Yes , I have had to put in an order at above 0.7 as the one at 0 7p just been rejected this minute

As we saw during the sickening riots? People cant just say what they think and then defend it as "opinion"

The toxic nonsense on LSE is just a toxic as those social media posts during the riots

It's not am opinion it's false and misleading as per FCA rules

Thankyou Mason

Yes..I was trying £1500 and also £2500 so have placed an order via NT

It will be removed as it is libelous, false and market abuse

It's that simple

I'm not able to get a qoute for much

GB

bio tech NT ..ready

In terms of value

1) recent dosing A.I software has been sold at $50mln and bought by GE

2) other software/diagnostic stocks such as GDR are valued at £15-20mln on fewer revenues

3) PYC us uniquely positioned within the new FDA guidelines on drug trials and kn fact has done and published articles on what FDA call "Project Optimus "

(See PYC LinkedIn posts etc last 12mths-15ths

The core business can turn a profit and new CEO has been ruthless in shedding dead wood ( see May 2024 board change...) and the size of contracts is now groung with the last 3 being largest single contracts in PYC history

What is really exciting is their dosing app software with US partner DoseMeRx

PYC us currently valued at only 1.5 x revenues!!....crazy

Docetaxel is predominantly used for prostate cancer and the tool is being developed for that however this maybe able to support other types of cancer moving forward…..route to market via Dosemerx

The precision application will save time in favour of the patient and hopefully help overall survival.

Naturally saving time and dosing will save significant amounts of money…

Docetaxel market size was valued at USD 114.78 billion in 2023 and it is estimated to reach USD 252.46 billion in 2032.

Below is an idea of size of prospect

Ilovesushi

You say this on every stock but then happy to be buying IMM which has no cash

Not a problem

Any other questions please ask, there are 4 or 5 knowledgeable people on here

In our belief a company like PYC at cutting edge of A.I in drug discovery with low cost base , record contracts signed and growing regulatory requirements for what PYC.offers should NOT be only valued at £.1.4mln ( with about £500£60pkncssh now after July funding)

A simple summary which hopefully answers your Q, other holders might correct/add

a) what are the main 'products' and offerings of PYC?

* use A.I and mathematical modelling to design and interpret data for drug companies

*therefore their main business is.software consultancy and work with medium and large companies often with long standing relationships and repeat business.

* they've also been designing a dosing tool to help with dosing regimes and this tool could be adopted by companies and generate significant revenues

* they are also setting up a biostatistics division as interpreting data is becoming more and more essential and in fact required by the FDA etc

b) how do they make money - one-offs, recurring revenue, long term contracts?

* they have moved in last 5 yrs from reliance on on major customer (Merck) to over 20-30 clients, many of which now place repeat business, they are also gaining new customers via social media awareness, industry initiatives.and global conferences

* many holders believe revenue sharing agreements should be the next step potential.

c) what realistically are the prospects for PYC

profits and more importantly for us as PI's the SP over the next 6,12 and 24 months?

* PYC won record contracts for 2023/24 of £900k+ and already have £500k booked in month 1 of this 12mth period (July 2024-june 2025) with estimates being that £1.2mln-£1.3mln should deliver profit

*growing need and awareness of A.I in drug development and now new FDA guidance that drug companies MUST have used data modelling means PYC.is well set for 2024+

d) linked to the above, what would be the catalyst(s) to PYC taking off?

( see the excellent summary from KingHomerJ which I posted 10pm last night )

I can see you've been investing in AIM for over 10yrs so I'm confident you'll find what you need by reading the PYC RNS

But any Qs just ask these board

This is severely undervalued at current MC.

Even at 2p (4 Million MC) its still a steal....lots of news to come to build from here.

* Highest Level of Revenue going into financial year £600k (We are 2 months into it)

* Dosemerx update & Collab

* NHS Prostate Cancer Trial ongoing - update due

* Beyond Blood Trial ongoing - update due (i would suggest people look at the shareholders on this one) Companies House

* Bicycle Therapeutics Update due - to be announced in September

* New Revenue Arm launched

* New Recruit has moved from AstraZeneca

* VAL 201 (Up to £6mil) if that ever ever ever happens who knows....

Hi Josh

I would certainly watch the last 3 IMC (INVESTOR MEET COMPANY) on YouTube

But in meantime Kinghomer gave some good summary recently

Physiomics plc

1,607 followers

7h

Model-Informed Drug Development (MIDD) is becoming indispensable in R&D decision-making and drug development. Merck Group highlights how MIDD enables timely decisions, reduces costs, and ensures that only the most promising candidates progress to late-stage clinical trials. 👇

With the FDA's latest guidance recommending MIDD to justify early dosing decisions for cancer therapies, our team at Physiomics plc is here to help. Our deep expertise in modelling and simulation can guide you in identifying optimal dosages, minimising risks, and boosting your chances of regulatory success. Reach out to learn more!

#FDA #Cancer #Modelling #Simulation #DrugDevelopment #Dosing #Biotech #Pharma #ClinicalTrails #CancerResearch #OptimalDose

It's very tight spread

0.67 to 0.69 ish

Erebuss

Watch the other one too (see previous messages gb.knows)